Japan approves AstraZeneca COVID drug Evusheld, Pfizer/BioNTech vaccine for kids 5-11
XtockImages/iStock via Getty Images         

A committee of Japan's Ministry of Health, Labour and Welfare approvedÂ AstraZeneca's COVID therapyÂ (NASDAQ:AZN)Â Evusheld.
The panel also approved the expanded use ofÂ Pfizer (NYSE:PFE) and BioNTech's (NASDAQ:BNTX) COVID-19 vaccineÂ Comirnaty for use in children aged five years to 11 years.
Earlier in August, U.K. halted procurement of Evusheld (tixagevimab/cilgavimab)Â citing "insufficient data" on the duration of protection the drug provides against Omicron and subvariants.